2026 ICD-10-CM Diagnosis Code E75.21Fabry (-Anderson) disease

ICD-10-CM Codes›E00–E89›E70-E88›E75

ICD-10-CM E75.21
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E75.21 is a billable ICD-10-CM diagnosis code for fabry (-Anderson) disease. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). Coders also document this condition as autonomic neuropathy due to Fabry disease. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.

Code Identity

ICD-10-CM Code
E75.21
Billable Status
Yes — Valid for Submission
Code Describes
Fabry (-Anderson) disease
Short Description
Fabry (-Anderson) disease
Same as the full description in the CMS dataset.
Parent Code
E75.2
Other sphingolipidosis

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE75Disorders of sphingolipid metabolism and other lipid storage disorders
This CodeE75.21Fabry (-Anderson) disease

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Autonomic neuropathy due to Fabry disease
  • Deficiency of alpha-galactosidase
  • Fabry's disease
  • Glomerular disease due to Fabry disease

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Anderson-Fabry disease
    • Angiokeratoma
      • corporis diffusum
    • Degeneration, degenerative
      • brain (cortical) (progressive)
        • in
          • Fabry-Anderson disease
    • Disease, diseased
      • Sweeley-Klionsky
    • Disorder(of)
      • glomerular (in)
        • Fabry's disease
    • Fabry(-Anderson) disease
    • Glomerulonephritis
      • in (due to)
        • Fabry (-Anderson) disease
    • Lipidosis
      • glycolipid
    • Sweeley-Klionsky disease

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Other Sphingolipidosis|Other sphingolipidosis

    evidence of other sphingolipidosis not specified elsewhere.

  • Sphingolipidosis

    an inherited metabolic disorder that affects the metabolism of the spinhgolipids. representative examples include gaucher disease, tay-sachs disease, and niemann-pick disease.

Patient EducationClinical

Genetic Brain Disorders

A genetic brain disorder is caused by a variation or a mutation in a gene. A variation is a different form of a gene. A mutation is a change in a gene. Genetic brain disorders affect the development and function of the brain.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E75.21 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
272.7 Lipidoses
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About E75.21Overview

Is E75.21 (Other sphingolipidosis) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report fabry (-Anderson) disease on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What is the ICD-9 equivalent of E75.21?

Under the General Equivalence Mappings, fabry (-Anderson) disease converts to ICD-9-CM 272.7 (lipidoses). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.